Table 1.

Comparison of Clinical Characteristics Between SLE Patients with METTL1 Low and High Expression

	Patients with METTL1 mRNA Low Expression (n=23)	Patients with METTL1 mRNA High Expression (n=22)	P
Female, n (%)	19 (82.61)	21 (95.45)	0.170
Vasculitis, n (%)	4 (17.39)	1 (4.55)	0.170
Myositis, n (%)	1 (4.35)	0 (0)	0.323
Fever, n (%)	7 (30.43)	5 (22.73)	0.559
Hypocomplementemia, n (%)	15 (65.22)	10 (45.45)	0.182
Pericarditis, n (%)	4 (17.39)	1 (4.55)	0.170
Pleuritis, n (%)	2 (8.70)	0 (0)	0.157
Oral ulcer, n (%)	3 (13.04)	2 (9.09)	0.673
Pneumonia, n (%)	1 (4.35)	1 (4.55)	0.974
Pyuria, n (%)	3 (13.04)	5 (22.73)	0.396
Proteinuria, n (%)	6 (26.09)	10 (45.45)	0.175
Hematuria, n (%)	6 (26.09)	3 (13.64)	0.297
Cylindruia, n (%)	4 (17.39)	0 (0)	0.127
Renal involvement, n (%)	10 (43.48)	9 (40.91)	0.862
Central nervous system involvement, n (%)	2 (8.70)	0 (0)	0.157
Arthritis, n (%)	9 (39.13)	6 (27.27)	0.399
Skin rash, n (%)	8 (34.78)	5 (22.73)	0.372
Anti-dsDNA, n (%)	7 (30.43)	1 (4.55)	0.060
Anti-SSA, n (%)	11 (47.83)	10 (45.45)	0.873
Anti-SSB, n (%)	1 (4.35)	1 (4.55)	0.974
Anti-Sm, n (%)	10 (43.48)	4 (18.18)	0.067
Anti-nRNP, n (%)	12 (52.17)	8 (36.36)	0.286
Anti-rRNP, n (%)	8 (34.78)	6 (27.27)	0.586
AuaA, n (%)	9 (39.13)	2 (9.09)	0.019
Anti-Histone, n (%)	5 (21.74)	3 (13.64)	0.477
ANA, n (%)	22 (95.65)	20 (90.91)	0.524
SLEDAI	13.52±13.46	6.68±6.61	0.038